ClinicalTrials.gg
Not yet recruitingNCT07949955ESRD and HWIUpdated Nov 19, 2026

Hot Water Immersion on Fluid Overload in People With End-stage Kidney Disease

An interventional study of Hot water immersion in End Stage Renal Disease / Hemodialysis, sponsored by University of Portsmouth. Not yet recruiting. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Portsmouth · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

Dialysis is important in treating people with end-stage kidney disease (ESKD) to remove excess water and toxins, maintaining quality of life (QoL) and to keep people alive. Where people with ESKD retain too much water (fluid overload), the amount of water removed and the speed of removal must be higher to meet the individual's needs and avoid short- and long-term negative consequences. This can be a particular issue for people on haemodialysis after a weekend, when there is a 2-day gap between dialysis sessions. Removing the larger quantities of water quickly (proportional to speed of removal) can lead to low blood pressure, reducing QoL and increasing the chance of getting heart and blood vessel disease and the risk of death. Additionally, the dialysis schedules, and lack of dialysis capacity, often means sessions cannot be extended, or patients are offered extra sessions for fluid removal. Given the need to reduce fluid overload and the difficulties people have sticking to fluid restrictions, (taken by mouth) other therapies are needed to improve outcomes and people's experiences.

One such possible therapy is to induce sweating via passive heating (i.e. sitting in hot tubs). Few studies have examined sweat loss rates with heating in people with ESKD. Given the potential cost-effective method for reducing excessive body water and improving QoL, there is little evidence with no data examining any associated cardiovascular or quality of life benefits.

Read the detailed description

Chronic kidney disease (CKD) affects \~10% of people worldwide and is characterised by progressive deterioration of renal function, which leads to increased morbidity and mortality. As CKD progresses, loss of renal function reduces sodium filtration, suppresses tubular reabsorption of electrolytes and results in fluid volume expansion that can lead to fluid overload. Fluid overload has numerous signs and symptoms, including oedema, shortness of breath, fatigue and hypertension. Fluid removal is critical in the treatment of CKD because fluid overload increases the risk of congestive heart failure, left ventricular hypertrophy and other cardiovascular sequelae and increased mortality. Current treatments include sodium restriction, diuretics, fluid restriction, lifestyle modifications, including alcohol restriction, weight management, exercise prescription. When people reach end-stage renal disease (ESRD), the kidneys no longer effectively remove toxins and manage fluid homeostasis. If a transplant is not available, then people are reliant on ultrafiltration on dialysis (either haemodialysis or peritoneal dialysis) to remain euvolaemic. Many of these treatments (especially for in-centre haemodialysis) have low levels of adherence and have a major impact on quality of life [21-24]. Moreover, large volume mechanical ultrafiltration and the rate of ultrafiltration on haemodialysis associates with cardiac functional changes directly linked to peoples outcomes. This is particularly relevant due to inflexible dialysis schedules (4 hours x 3 times weekly) and lack of dialysis capacity; it is not always feasible to reduce the rate of ultrafiltration either by extending the session or offering an extra session. Exploring adjunct treatments to manage fluid overload to improve patient outcomes and experience are warranted.

Dialysis is critical in the management of ESRD to keep people alive and to maintain quality of life (QoL). In people with fluid overload there is a particular need for higher ultrafiltration volumes (and rates) (i.e. fluid removal via dialysis) to maintain dry weight (i.e. mass without fluid overload) to reduce the risk of acute and chronic adverse events. This can be a particular issue for people on haemodialysis after the long 2-day gap. However, large ultrafiltration volumes and increased UF rates can lead to intradialytic hypotension (IDH), dizziness, nausea, headaches and cramping. Importantly, IDH increases the risk of cardiovascular disease and all-cause mortality and is linked to myocardial stunning events that are driven by large volume ultrafiltration. Given the need to reduce fluid overload and the difficulties patients have sticking to fluid restrictions exploration of alternative therapies is warranted.

One such possible therapy is to induce fluid loss via sweating via passive heating. Commonly administered through hot water immersion (HWI), this limits evaporative heat loss to the areas not immersed and, in conjunction with the high thermal conductivity of water, rapidly increases deep body temperature, ultimately leading to increased sweating. Multiple studies have shown sweat loss rates of \~1L‧h-1 with passive heating in healthy people, whilst in individuals with CKD sweat loss is \~0.6-0.8 L‧h-1. Given the potential cost-effective method for reducing fluid overload, there is a paucity of evidence on induced diaphoresis in people with CKD. Modalities of heating that have been used in people with CKD include; exercise, saunas and bath tubs with no data examining any associated metabolic, cardiovascular or quality of life benefits.

Passive heating has also been linked to improvements in metabolic and cardiovascular function by both intra and extracellular mechanisms. We recently reported that 8-10 HWIs within a 14-day period improves fasting insulin sensitivity, plasma [insulin], cardiac output, stroke volume and blood pressure (BP) in individuals with Type 2 Diabetes Mellitus (T2DM). Whilst other groups report similar findings on metabolic and cardiovascular function in healthy individuals and other clinical cohorts. Passive heating increases the cellular protective chaperones known as heat shock proteins (HSP) which may in part explain some of these beneficial effec ts. Passive heating increases [HSP72] (in skeletal muscle), [HSP70] and [HSP27], which reduces inflammatory transcription factors, upregulate glutathione redox cycle and increases endothelial nitric oxide synthase.

02

Conditions studied

  • End Stage Renal Disease / Hemodialysis
03

In context

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

This study's planned enrollment of 14 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

University of Portsmouth is the lead sponsor of 34 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female, aged 16 years or above.
  • Diagnosed with ESRD of any aetiology
  • Undergoing in centre haemodialysis treatment three times weekly for 4 hours per session
  • Has been on HD for at least 6 months
  • Is not on
  • Participant is willing and able to give for participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Severe peripheral neuropathy (to the point where they cannot sense temperature).
  • Skin ulcerations
  • Eczema
  • Pre-existing postural hypotension
  • Uncontrolled hypertension (≥180 systolic / 100 diastolic mmHg).
  • Taking any medication which may interfere with data interpretation or safety
  • Taking any oral medication (excluding prednisolone up to 5mg) or having had intravenous immunosuppressive agents (cyclophosphamide, rituximab, or similar) in the 6 months preceding the start of the study
  • Any other serious medical condition which would interfere with data interpretation or safety will be excluded from participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    Hot water immersion

    Daily passive heating: Participants will attend the laboratory on 4 occasions within a period of 7 days (\~ 90 min per visit) at any point in the day (standardised within participant). Anyone completing less than 3 sessions will be excluded from analysis. During each visit participants will self-insert a rectal thermistor (shown to a private room and given instruction) and will then be immersed into a hot tub (\~ 40 oC) for 60 min. Body position will be manipulated as required to achieve and maintain a target Trec at 38.5-39.0oC using 40oC water. Participants will be required to wear a bathing suit and a t-shirt for all heating visits.

    Other: Hot water immersion

  • No intervention
    Control

    Participants in this arm will receive usual care, consisting of standard clinical management provided as part of routine healthcare practice. No additional intervention will be administered by the study team.

Interventions

  • OtherHot water immersion

    Daily passive heating: Participants will attend the laboratory on 4 occasions within a period of 7 days (\~ 90 min per visit) at any point in the day (standardised within participant). Anyone completing less than 3 sessions will be excluded from analysis. During each visit participants will self-insert a rectal thermistor (shown to a private room and given instruction) and will then be immersed into a hot tub (\~ 40 oC) for 60 min. Body position will be manipulated as required to achieve and maintain a target Trec at 38.5-39.0oC using 40oC water. Participants will be required to wear a bathing suit and a t-shirt for all heating visits.

06

What researchers measure

Primary outcomes

  1. Interdialytic Weight Gain (IDWG):

    IDWG will be calculated for each dialysis session and will be computed as the difference between the persons pre-dialysis weight and their post-dialysis weight ( IDWG= current pre dialysis weight - previous post dialysis weight). These values will then be averaged to produce the weekly IDWG estimate.

    Time frame: through study completion, average 1 week

  2. Deviation from Dry Weight:

    Over the same one-week time frame, the average difference between the post-dialysis weight and the prescribed dry weight will be calculated for all dialysis sessions. This metric reflects the persons achievement of euvolemia at the end of treatment. Positive values indicate residual fluid excess, while negative values indicate post-dialysis weight below the targeted dry weight.

    Time frame: through study completion, average 1 week

Secondary outcomes

  1. Weight

    Sweat loss will be recorded for each hot tub immersion. Immediately prior to immersion and immediately after immersion following be towel dried. Both assessments are done nude whilst de-instrumented. Any

    Time frame: through study completion, average 1 week

  2. Quality of Life - Kidney Disease Quality of Life Instrument

    The Kidney Disease Quality of Life Instrument (KDQoL-36) scale has been shown to have high reliability and validity \[53\]. The KDQoL is freely available at https://www.rand.org/health/surveys/kdqol.html and contains 24 questions.

    Time frame: through study completion, average 1 week

  3. Quality of life - World Health Organisation quality of life (WHOQOL-BREF).

    The WHOQOL-BREF is a 26-item self-report questionnaire developed by the World Health Organization to assess an individual's perceived quality of life, and has been shown to have high reliability and validity \[54\]. The WHOQOL-BREF is freely available at https://www.who.int/tools/whoqol/whoqol-bref.

    Time frame: through study completion, average 1 week

  4. Systolic blood pressure

    Resting systolic blood pressure will be measured five times and recorded as the average of the final three measurements.

    Time frame: through study completion, average 1 week

  5. Diastolic blood pressure

    Resting diastolic blood pressure will be measured five times and recorded as the average of the final three measurements

    Time frame: through study completion, average 1 week

  6. Mean arterial pressure

    Resting mean arterial pressure will be measured five times and recorded as the average of the final three measurements

    Time frame: through study completion, average 1 week

  7. cardiac output

    Using thoracic bio-reactance technology (Physioflow), which will derive cardiac output at rest. Six electrodes are placed on the participant's chest and neck between which a small, painless current is passed.

    Time frame: through study completion, average 1 week

  8. Macrovascular function

    rachial artery FMD will be used as a measure of endothelial function \[69\]. Endothelial-dependent function is assessed by measuring FMD in response to a 5 minute ischaemic stimulus, induced by forearm cuff inflation \[69\]. Measurements will be performed in the supine position on the right arm (if fistula is present, technique will be run on left arm) with the cuff placed distal to the olecranon process. High-resolution duplex ultrasound (Terason uSmart 3300, Teratech, Burlington, MA) with a 15.0-4.0-MHz linear wideband array probe will be used to image the brachial artery at the distal third of the upper arm and simultaneously record the longitudinal B-mode image and Doppler blood velocity trace. The angle of Doppler insonation will be 60°.

    Time frame: through study completion, average 1 week

  9. Assessment of inferior vena cava

    Assessing diameter and collapsibility with inspiration can provide an indirect assessment of central venous (right atrial) pressure. Using a standard, low-frequency (ultrasound) probe the IVC diameter in M-mode is measured approximately 1-2 cm distal to the junction of the hepatic vein and the right atrium. The diameter is measured during expiration (maximum) and during inspiration (sniff, minimum).

    Time frame: through study completion, average 1 week

  10. Microvascular function

    Individuals will be acclimated for a minimum of 30 minutes in an ambient temperature of 23 ºC prior to acetylcholine (ACh) and sodium nitroprusside (SNP) being delivered transdermally via iontophoresis to volar aspect of the left forearm.

    Time frame: through study completion, average 1 week

  11. Cognitive performance

    Cognitive performance will be assessed using a four-task cognitive battery administered on a laptop computer using commercially available testing software (ANAM: Automated Neurophysiological Assessment Metrics, developed for the US Department of Defence and licensed by Vista Life Sciences). For each task, scoring will be based on accuracy and/or response time. Completion of the test requires the participant to use a normal computer mouse, which has been deemed a suitable method to test cognitive function in older adults (Zygouris \& Tsolaki, 2015). Participants will be familiarised with the ANAM software, where they will complete the testing battery 3-5 times until their performance has plateaued. The ANAM software manual states that the programme has test-retest reliability for over one year, therefore participants will not need to be refamiliarised with the software before their final experimental visit.

    Time frame: through study completion, average 1 week

  12. Interviews

    Qualitative sub-studies will explore study feasibility, acceptability, and participants' overall experiences. In terms of the acceptability, the study will explore it based on the Theoretical Framework of Acceptability \[55\]. It will explore participants affective attitudes towards the intervention, the burden the intervention might be to the participants, the perceived effectiveness and the user experience of the intervention, the intention of the participants to take part in the intervention. The interviews will take place during the fourth visit irrespective of the intervention sequence.

    Time frame: through study completion, average 1 week

  13. Total body water:

    Total body water content will be assessed via bioelectrical impedance using a single-frequency hand-to-foot device (Bodystat 1500, Bodystat Ltd., Douglas, Isle of Man, United Kingdom). The participants' height, age, sex, weight, frame size, and activity level will first be inputted to the device. Participants will then lie supine on a bed with legs slightly apart and arms at an approximate 30° angle to the body. Four adhesive electrodes will be attached to the dorsal surfaces of the right hand and right foot. Prior to electrode placement, the four placement sites will be cleaned with an alcohol swab. Participants will be instructed to lie completely still while the measurement is taken.

    Time frame: through study completion, average 1 week

  14. Perceptual measures of heat stress:

    Thermal comfort and sensation scales will be used during the investigation to provide a subjective rating of how the participants are feeling within the environment. For thermal comfort participants will be asked to rate their perception of satisfaction of the environment from their state of mind. For thermal sensation, participants will be asked to rate their perception of the sensory feeling of the environment around them. Both questions will be measured on a six-point and six-point scale respectively. This will provide a more in detail understanding of the sensory and state of mind of thermal perception. Participants will be provided with a pen and will be asked to draw a line onto the scale regarding their answer. This will then be measured on a visual analogue scale, and be recorded in cm (Stevens et al., 2025). The marker location will be taken as the uppermost and leftmost extent of the ink marking drawn by participants.

    Time frame: through study completion, average 1 week

  15. plasma [Troponin]

    A sample will be drawn at each specified visit/time point into a single 10 mL ethylenediaminetetraacetic acid (EDTA) tube (K2, BD, USA) for analysis of plasma \[Troponin\]

    Time frame: through study completion, average 1 week

  16. plasma [NTproBNP]

    A sample will be drawn at each specified visit/time point into a single 10 mL ethylenediaminetetraacetic acid (EDTA) tube (K2, BD, USA) for analysis of plasma \[NTproBNP\]

    Time frame: through study completion, average 1 week

  17. plasma [HSP70].

    A sample will be drawn at each specified visit/time point into a single 10 mL ethylenediaminetetraacetic acid (EDTA) tube (K2, BD, USA) for analysis of plasma \[HSP70\].

    Time frame: through study completion, average 1 week

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Apr 2028, 17 months later.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 17 months is below that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2026
First posted
Nov 19, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Apr 1, 2028
CompletionEst.
Apr 1, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949955
Lead sponsor
University of Portsmouth
Collaborators
Portsmouth Hospitals NHS Trust, University of Southampton, Bangor University
Responsible party
Ant Shepherd (Professor of Clinical Environmental Physiology, University of Portsmouth) — Principal investigator
First posted
Nov 19, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Apr 1, 2028 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Daniel Piccolo, PhD
Contact
daniel.piccolo@port.ac.uk
+44
Ant I Shepherd, PhD
Contact
ant.shepherd@port.ac.uk
+44239284 ext. 5289
Ant Shepherd, PhD
principal investigator · University of Portsmouth

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion